# **Screening Libraries**

# **Product** Data Sheet



# Pimobendan hydrochloride

Cat. No.: HY-B0204A CAS No.: 77469-98-8 Molecular Formula:  $C_{19}H_{19}CIN_4O_2$ 

Molecular Weight: 370.83

Target: Phosphodiesterase (PDE) Pathway: Metabolic Enzyme/Protease

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

**HCI** 

### **BIOLOGICAL ACTIVITY**

### Description

Pimobendan hydrochloride (UD-CG115 hydrochloride) is a selective inhibitor of PDE3 with IC<sub>50</sub> of 0.32 μM.

### In Vitro

Pimobendan hydrochloride (UD-CG115 hydrochloride) exhibits selective inhibition of PDE III isolated from guinea pig cardiac muscle with IC<sub>50</sub> of 0.32 uM compared to the inhibition of PDE I and PDE II (IC<sub>50</sub> > 30  $\mu$ M). In human atrial cells, 100  $\mu$ M Pimobendan (UD-CG115) significantly increases the L-type calcium current (ICa(L)) (evoked by depolarization to +10 mV from a holding potential of -40 mV) by 250.4% with the half-maximal stimulation (EC<sub>50</sub>) of 1.13 µM. In rabbit atrial cells, Pimobendan (UD-CG115) increases ICa(L) at +10 mV by 67.4.%, which is significantly lower than that obtained in human atrial cells.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### In Vivo

Pimobendan (UD-CG115) shows a beneficial effect on survival in the murine model of EMC virus-induced myocarditis. Administration of Pimobendan (UD-CG115) significantly increases the final survival rate from 33.6% (control) to 53.3% (0.1 mg/kg) or 66.7% (1 mg/kg). Pimobendan (UD-CG115) (1 mg/kg) also significantly reduces myocardial cellular infiltration, the level of intracardiac tumor necrosis factor (TNF)- $\alpha$  and interleukin (IL)-1 $\beta$  compared with the control group, which shows no effect on myocardial necrosis, heart weight and body weight. Pimobendan (UD-CG115) suppresses expression of the intracardiac iNOS gene, causing reduction of intracardiac NO production<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **PROTOCOL**

# Animal

Administration [2]

Mice<sup>[2]</sup>

Since, in this model, most mice die of congestive heart failure within 14 days after EMC virus inoculation (21), the survival was observed up to 14 days in this study. Pimobendan was administered in doses of 0.1 mg/kg or 1 mg/kg daily for 14 days from the day of EMC virus inoculation while control mice received vehicles only. Thirty mice were randomly assigned to each group<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **CUSTOMER VALIDATION**

• Sci Signal. 2020 Nov 24;13(659):eaax0273.

See more customer validations on  $\underline{www.MedChemExpress.com}$ 

### **REFERENCES**

[1]. Kajimoto K, et al. Contribution of phosphodiesterase isozymes to the regulation of the L-type calcium current in human cardiac myocytes. Br J Pharmacol. 1997 Aug;121(8):1549-56.

[2]. Iwasaki A, et al. Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis. J Am Coll Cardiol. 1999 Apr;33(5):1400-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com